Organon & Co. Hits New 52-Week High at USD 13.63

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.63 on August 10, 2026. This achievement marks a notable rebound from its 52-week low of USD 5.69, showcasing a substantial increase in market performance. Despite a challenging year, with a one-year performance decline of 34.23%, Organon & Co. has demonstrated resilience in its stock price movement. The company currently holds a market capitalization of USD 1,520 million, reflecting its position within the small-cap category. Key financial metrics reveal a price-to-earnings (P/E) ratio of 3.00, indicating a potentially attractive valuation compared to industry standards. Additionally, the company boasts a return on equity of 69.90%, highlighting effective management of shareholder funds. With a dividend yield of 1.02% and a debt-to-equity ratio of 10.78, Organon & Co. continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry.